Leerink Partnrs Issues Negative Forecast for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Leerink Partnrs cut their Q2 2025 EPS estimates for CRISPR Therapeutics in a report released on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.45) per share for the quarter, down from their prior estimate of ($1.38). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.54) EPS, Q4 2025 earnings at ($1.46) EPS, FY2025 earnings at ($6.03) EPS and FY2026 earnings at ($6.02) EPS.

Several other research firms have also commented on CRSP. Morgan Stanley increased their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a research note on Friday, February 14th. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research note on Thursday. Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and raised their price target for the company from $60.00 to $99.00 in a report on Friday, February 14th. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Finally, Royal Bank of Canada decreased their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Trading Up 5.5%

Shares of CRSP traded up $1.97 on Friday, reaching $37.59. The company's stock had a trading volume of 1,959,320 shares, compared to its average volume of 1,670,582. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $67.88. The stock has a market capitalization of $3.25 billion, a PE ratio of -8.60 and a beta of 1.88. The firm has a fifty day moving average of $38.15 and a 200-day moving average of $42.71.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter in the prior year, the firm posted ($1.43) EPS. The company's quarterly revenue was up 71.6% compared to the same quarter last year.

Insiders Place Their Bets

In other news, COO Julianne Bruno sold 1,198 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. This represents a 12.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now owns 77,530 shares in the company, valued at approximately $3,288,822.60. This represents a 3.55% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of CRISPR Therapeutics in the first quarter worth approximately $477,000. Benjamin Edwards Inc. lifted its position in CRISPR Therapeutics by 13.0% during the first quarter. Benjamin Edwards Inc. now owns 50,915 shares of the company's stock valued at $1,733,000 after purchasing an additional 5,853 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in CRISPR Therapeutics by 9.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,725 shares of the company's stock valued at $195,000 after purchasing an additional 473 shares during the period. Vanguard Group Inc. lifted its position in CRISPR Therapeutics by 1.9% during the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company's stock valued at $60,223,000 after purchasing an additional 33,711 shares during the period. Finally, Costello Asset Management INC bought a new position in CRISPR Therapeutics during the first quarter valued at approximately $27,000. Institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.